Exelixis (EXEL) Total Current Liabilities (2010 - 2026)
Exelixis' (EXEL) quarterly Total Current Liabilities came in at $371.0 million in Q2 2026, down 7.05% year-on-year from $399.1 million in Q2 2025, and down 8.55% quarter-over-quarter from $405.6 million in Q1 2026.
Exelixis (EXEL) Total Current Liabilities (2010 - 2026) Analysis & Trends
Exelixis' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $371.0 million for Q2 2026.
- On a quarterly basis, Total Current Liabilities fell 7.05% year-over-year to $371.0 million in Q2 2026; TTM through Apr 2026 was $371.0 million, a 7.05% decrease from a year earlier, with the FY2026 full-year figure at $405.6 million, changed 0.46% from the prior year.
- Total Current Liabilities eased to $371.0 million in Q2 2026 per EXEL's latest filing, from $405.6 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $405.6 million in Q1 2026 and bottomed at $289.1 million in Q2 2022.
- The 5-year median for Total Current Liabilities is $371.0 million (2026), against an average of $356.5 million.
- Across the five-year window, Total Current Liabilities jumped 35.5% in 2022 and fell 7.05% in 2026, its largest moves.
- Year by year, Total Current Liabilities stood at $324.4 million in 2022, then advanced by 21.56% to $394.3 million in 2023, then climbed by 0.02% to $394.3 million in 2024, then declined by 5.22% to $373.8 million in 2025, then fell by 0.75% to $371.0 million in 2026.
- Per Business Quant, the three latest EXEL Total Current Liabilities figures stand at $371.0 million (Q2 2026), $405.6 million (Q1 2026), and $373.8 million (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | Exelixis | 14.38 Bn | 13.60 Bn | 590.86 Mn | 370.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 370.98 Mn |
| Jan 2, 2026 | 405.64 Mn |
| Oct 3, 2025 | 373.78 Mn |
| Jul 4, 2025 | 336.11 Mn |
| Apr 4, 2025 | 399.10 Mn |
| Jan 3, 2025 | 403.77 Mn |
| Sep 27, 2024 | 394.35 Mn |
| Jun 28, 2024 | 345.70 Mn |
| Mar 29, 2024 | 373.01 Mn |
| Dec 29, 2023 | 394.28 Mn |
| Sep 29, 2023 | 376.82 Mn |
| Jun 30, 2023 | 339.62 Mn |
| Mar 31, 2023 | 327.60 Mn |
| Dec 30, 2022 | 324.36 Mn |
| Sep 30, 2022 | 301.73 Mn |
| Jul 1, 2022 | 304.52 Mn |
| Apr 1, 2022 | 289.08 Mn |
| Dec 31, 2021 | 337.59 Mn |
| Oct 1, 2021 | 269.51 Mn |
| Jul 2, 2021 | 255.33 Mn |